Skip to content
  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
Daily News India

Daily News India

Just another WordPress site

  • English
  • Business
  • Entertainment
  • National
  • Lifestyle
  • Education
  • Toggle search form
  • GRM Overseas expanded its 10X Ready to Cook Biryani Portfolio with Two New Flavours Awadhi and Lucknowi Biryani Kit Lifestyle
  • StudioBackdrops Is Rewiring India’s Creator Economy — Much Like Jio Did for Internet Access Technology
  • Digicops Legal Consultancy India Pvt Ltd, rolling out in Ahmedabad, Baroda, Surat, Rajkot for FSSAI licensing Business
  • World Best Brand & Business Awards 2021(2nd Edition) Held Successfully In Mumbai, Felicitated Entrepreneurs, Organisations & Start-Ups Business
  • Love Aaj Kal: Pinky Promise Analyses 10,000 Conversations on Women and Pleasure Business
  • Satyam Kantamneni of UXReactor Hosts a Book Discussion Event for an Active Discourse on His Book on UX Design Business
  • When Silent Losses Turn Into a Mission – The Story Behind OiGenie Business
  • Research Study Explores Ideological Differences Between Orphan Care and Family Care in Literature and Society Lifestyle

Optimus PharmaSeeks Emergency Approval to Conduct Phase 3 Clinical Trial of Molnupiravir for COVID-19 in India

Posted on April 27, 2021 By

Hyderabad [Telangana], April 27: Dr. D. Srinivas Reddy, Chairman, and CEO of Optimus Pharma announced that they have filed for seeking emergency approval for Phase 3 Clinical Trial from the Drugs Controller General of India. Once the approval is granted for Phase 3 Clinical Trial, we would be extensively accelerating the manufacturing of our in-house developed generic version of Molnupiravir for making it available in the Indian market as soon as possible. Optimus Pharma is committed to halting the pandemic across the nation and ensuring immediate relief to all those who have been infected with the highly virulent SARS-CoV-2.

Optimus Pharma is pleased to announce the development of oral Molnupiravir on the fast lane. Optimus Pharma is becoming a key player in the fight against the COVID-19 pandemic in India has already achieved very high production levels of Favipiravir one of our flagship drugs for COVID-19 infection. In a bid to develop and diversify our anti-viral portfolio especially against SARS-CoV-2, we are here with yet another promising drug to compensate for the lack of antiviral drugs in the market further diversifying our antivirals portfolio. In hindsight of the raging second wave, Molnupiravir has been developed for non-hospitalized mild to moderate infections of SARS-CoV-2. Optimus Pharma is aggressively pushing for achieving scalability for 800mg dose of the drug.

Our available pre-clinical data on Molnupiravir already demonstrated that there were no adverse clinical signs and mortality observed in any of the treatment groups, as compared to the control group of animals with high efficacy and thereby effectively neutralizing virulence of the SARS-CoV-2 virus in the test group as compared to control group.

The drug is effective against a variety of viruses that use an RNA-dependent RNA polymerase (RdRp), as is the case with SARS-CoV-2 which is directly responsible for the transcription of Viral m-RNA of the virus in the infected subject. Early in vitro tests of Molnupiravir on SARS-CoV-2 revealed a steady decrease in virus output that was proportional to the dose of Molnupiravir used. Since the RdRp of SARS-CoV-2 and SARS-CoV, which the drug was designed to treat, has 99.1% nucleotide similarity hence, this was possible. Repeated drug exposure quickly neutralized virus populations, ensuring that none of the random mutations mediate drug resistance. As the drug is introduced in higher amounts, the titer levels and genome output of SARS-CoV-2 decrease exponentially.

It has been observed that Molnupiravir is only marginally successful in preventing extreme SARS-CoV-2 infection that is severe cases of the infection. This might have been the reason for their withdrawal and continue the trial only with non-hospitalized patients that are subjects with mild to moderate infection. We aim to do the same and establish its efficacy in the same treatment group.

Phase 2 Clinical Trial study on enrolled 202 non-hospitalized adults is already made available by the innovator of the molecule. Virological analysis was characterized by a marked decrease in positive viral culture in subjects who received Molnupiravir (all doses) relative to placebo – at day 5: 0% (0/47) for Molnupiravir and 24% (6/25) for placebo. Furthermore, the secondary objective for a faster decrease in infectious virus among people with early COVID-19 who were treated with Molnupiravir is encouraging and Phase 3 Clinical Trials are warranted for checking the efficacy of the molecule across demographics, particularly as the SARS-CoV-2 virus continues to spread and evolve globally.

Unlike the current drugs being administered intravenously, Molnupiravir is administered orally. This makes it a promising drug to halt the disease progression in the early stages as well as mount a powerful response against moderate infection levels. The fact that this molecule can be consumed as an orally administered drug in the form of an 800mg capsule renders a maverick advantage to achieve scalability in terms of upscaling from gm scale to multi-ton levels in a short time frame, thereby ensuring availability in the Indian market at a comparatively exponential scale. In vitro assays indicate that it is significantly more effective than the drugs being used currently, and the safety profile appears to be satisfactory.

English, Health Tags:DrDSrinivasReddy, OptimusPharmaSeeks, PNN

Post navigation

Previous Post: Indian Leadership Academy – A one-stop destination for all your training and coaching needs in Leadership and mindful learning
Next Post: XERTZ launches first-ever true wireless stereo technology-based Audio-frame glasses and sunglasses for the Indian market

Related Posts

  • Plan My Health & Educure delivering all kind of Digital preventive & Online wellness Services to Corporate, Schools & families English
  • Winter and Pollution: An Emerging Health Hazard – Can Nutrition Help Counter This Threat Health
  • Better health of healthcare workers in India: A Closer Look Insights by Dr. Gopal Sharan MD & CEO of TRLS Healthcare Consultancy Health
  • Dr Amit Jain – The Father of Diabetic foot surgery (Podiatry) is breaking boundaries and sets new world record Health
  • Holi and Your Skin: A Dermatologist’s Advice By Dr. Jagdish Sakhiya, MD Dermatologist Health
  • Lung cancer awareness month: advice by 5 best cancer specialists Health

Recent Posts

  • PPFAS Asset Management appoints Devendra Ghalsashi as Chief Operating Officer
  • Irfan Pathan and Adah Sharma Grace the Launch of Youth Cricket League’s YCLT10
  • From Military Service to Social Change: Ramesh Sangle Explores Nation-Building in BRIGADE
  • Samiran Tea Unveils New Product Portfolio, Including 10 Herbal Tea Blends, at Noida Office Inauguration
  • Manav’s ‘Bardic Voices: Where the Horizon Meets, the Magic Begins’ Explores Memory, Humanity, and the Search for Meaning

Recent Comments

  • Unknown on Participants Reap Rewards in Wellman’s 8-Week Digital Campaign: IPL Tickets, Autographed Virat Kohli Merchandise, and More!
  • Filter Crown Announces National Winners Across Art, Literature, Dance, and Music Competitions Lifestyle
  • India Must Treat Buildings as Products, Not Projects Business
  • HIWAGA Launches Skin, Hair & Aesthetics Centre in Bengaluru Business
  • Why Registered Chit Funds Are Becoming a Preferred Financial Planning Option in Kerala Finance
  • Daikoku Innovations: Paving India’s Rise in Electronic Product Development Business
  • Indian Students in the US Become the Most Preferred Hiring Pool Amid USD 100K Visa Fee Drop for F-1 Students Already in the Country Business
  • The Majesty Continues: Paurashpur 2 Trailer Unveiled, Premiere Date Set for July 28, 2023! Entertainment
  • Utkarsh Saxena is all geared up for Tum Bhi Pachtaoge featuring Mohd Sharia Entertainment

Copyright © 2026 Daily News India.

Powered by PressBook News WordPress theme